Aptevo Therapeutics Q2 EPS $(1.23) Misses $(1.12) Estimate
Portfolio Pulse from Benzinga Newsdesk
Aptevo Therapeutics reported Q2 losses of $(1.23) per share, missing the analyst consensus estimate of $(1.12) by 9.82 percent. However, this is a 32.42 percent increase over losses of $(1.82) per share from the same period last year.
August 10, 2023 | 12:20 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Aptevo Therapeutics' Q2 earnings per share missed estimates, but showed a year-over-year improvement.
Aptevo Therapeutics reported a larger loss than expected for Q2, which could negatively impact investor sentiment and the stock price. However, the year-over-year improvement might mitigate some of this negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100